IGFBP2's role in CVD may be multifactorial, with associations also shown with intima-media thickness and myocardial infarction, while data on cardiometabolic endpoints such as obesity and metabolic syndrome paradoxically show negative correlations with IGFBP2 in literature (78–80). Here, IGFBP2 is linked to metabolic syndrome.